Quantinno Capital Management LP Trims Holdings in Bio-Rad Laboratories, Inc. $BIO

Quantinno Capital Management LP decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.1% in the first quarter, HoldingsChannel reports. The firm owned 33,650 shares of the medical research company’s stock after selling 2,585 shares during the quarter. Quantinno Capital Management LP’s holdings in Bio-Rad Laboratories were worth $9,380,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Hound Partners LLC raised its position in Bio-Rad Laboratories by 125.9% during the 1st quarter. Hound Partners LLC now owns 97,724 shares of the medical research company’s stock worth $27,241,000 after buying an additional 54,456 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Bio-Rad Laboratories in the first quarter worth $5,098,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Bio-Rad Laboratories during the first quarter worth $4,388,000. Lido Advisors LLC acquired a new position in Bio-Rad Laboratories during the first quarter valued at $225,000. Finally, Cetera Investment Advisers boosted its holdings in Bio-Rad Laboratories by 0.6% in the first quarter. Cetera Investment Advisers now owns 7,596 shares of the medical research company’s stock valued at $2,117,000 after purchasing an additional 48 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 0.5%

BIO stock opened at $332.87 on Wednesday. The company’s 50-day simple moving average is $301.02 and its 200-day simple moving average is $287.81. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. Bio-Rad Laboratories, Inc. has a 52-week low of $236.73 and a 52-week high of $343.12. The firm has a market cap of $8.91 billion, a P/E ratio of 54.84 and a beta of 1.06.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.87. The firm had revenue of $651.00 million during the quarter, compared to analyst estimates of $623.99 million. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.Bio-Rad Laboratories’s revenue for the quarter was down .1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.61 EPS. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 9.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BIO. Royal Bank Of Canada started coverage on Bio-Rad Laboratories in a research note on Friday, May 15th. They set an “outperform” rating and a $320.00 price objective for the company. Zacks Research cut Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Weiss Ratings lowered Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Wells Fargo & Company lowered their price objective on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Finally, Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their target price for the company from $375.00 to $300.00 in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Reduce” and a consensus target price of $303.33.

Bio-Rad Laboratories News Summary

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Bio-Rad reported second-quarter adjusted earnings of $2.62 per share, exceeding analyst estimates of $1.75–$2.34 and roughly matching the $2.61 earned in the prior-year quarter. Revenue of $651 million also surpassed the approximately $624 million consensus estimate. Bio-Rad Laboratories Beats Q2 Earnings Estimates
• Positive Sentiment: Profitability and liquidity remained supportive: gross profit increased modestly to $345.8 million, operating cash flow was $98.7 million, and cash and equivalents rose to approximately $517 million. A large reported net-income figure was also boosted by items beyond operating performance, making adjusted EPS the more relevant measure for investors. Bio-Rad Laboratories Stock Falls on Q2 2026 Earnings
• Neutral Sentiment: Management’s second-quarter earnings call provided additional detail on the results and outlook, which investors will use to assess demand trends, margins, and execution through the rest of 2026. Bio-Rad Laboratories Q2 2026 Earnings Call Transcript
• Negative Sentiment: Revenue declined about 0.1% year over year, while operating profit eased to $72.6 million. The limited top-line growth is a concern because Bio-Rad’s valuation is elevated, with a reported price-to-earnings ratio above 50.
• Negative Sentiment: Bio-Rad guided to fiscal 2026 revenue of $2.5 billion–$2.6 billion, versus consensus of approximately $2.6 billion. The lack of a clearly stated EPS outlook and the lower end of the sales range likely tempered the positive impact of the quarterly earnings beat. Bio-Rad Laboratories Quarterly Earnings Results

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.